Barclays PLC Enanta Pharmaceuticals Inc Transaction History

Barclays PLC

$357 Billion
Q4 2024

A detailed history of Barclays PLC transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Barclays PLC holds 45,508 shares of ENTA stock, worth $308,089. This represents 0.0% of its overall portfolio holdings.

Number of Shares

45,508

Previous 27,438 65.86%

Holding current value

$308,089

Previous $285,000 8.07%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$5.75 - $12.99 $103,902 - $234,729	18,070 Added 65.86%	45,508 $262,000
Q3 2024 Nov 15, 2024	BUY	$10.05 - $16.54 $205,803 - $338,706	20,478 Added 294.22%	27,438 $285,000
Q2 2024 Aug 14, 2024	SELL	$11.43 - $17.02 $81,838 - $121,863	-7,160 Reduced 50.71%	6,960 $90,000
Q1 2024 May 15, 2024	SELL	$10.08 - $17.46 $273,974 - $474,562	-27,180 Reduced 65.81%	14,120 $246,000
Q4 2023 Feb 15, 2024	BUY	$8.18 - $10.78 $196,982 - $259,593	24,081 Added 139.85%	41,300 $388,000
Q3 2023 Nov 07, 2023	SELL	$11.09 - $22.13 $373,566 - $745,449	-33,685 Reduced 66.17%	17,219 $193,000
Q2 2023 Aug 03, 2023	BUY	$20.68 - $39.85 $509,844 - $982,461	24,654 Added 93.92%	50,904 $1.09 Million
Q1 2023 May 04, 2023	SELL	$38.82 - $54.59 $956,874 - $1.35 Million	-24,649 Reduced 48.43%	26,250 $1.06 Million
Q4 2022 Feb 13, 2023	BUY	$40.77 - $53.73 $225,498 - $297,180	5,531 Added 12.19%	50,899 $2.37 Million
Q3 2022 Nov 03, 2022	BUY	$48.29 - $71.27 $1.91 Million - $2.82 Million	39,571 Added 682.61%	45,368 $2.35 Million
Q2 2022 Aug 12, 2022	SELL	$38.13 - $76.93 $349,766 - $705,678	-9,173 Reduced 61.28%	5,797 $274,000
Q1 2022 May 16, 2022	SELL	$56.06 - $74.11 $564,412 - $746,139	-10,068 Reduced 40.21%	14,970 $1.07 Million
Q4 2021 Feb 14, 2022	BUY	$60.19 - $97.37 $137,293 - $222,100	2,281 Added 10.02%	25,038 $1.87 Million
Q3 2021 Nov 09, 2021	BUY	$41.02 - $58.65 $473,657 - $677,231	11,547 Added 103.01%	22,757 $1.29 Million
Q2 2021 Aug 13, 2021	SELL	$43.76 - $53.11 $539,429 - $654,686	-12,327 Reduced 52.37%	11,210 $495,000
Q1 2021 May 13, 2021	SELL	$41.69 - $54.95 $51,403 - $67,753	-1,233 Reduced 4.98%	23,537 $1.16 Million
Q4 2020 Feb 11, 2021	SELL	$41.16 - $47.47 $60,134 - $69,353	-1,461 Reduced 5.57%	24,770 $1.04 Million
Q3 2020 Nov 12, 2020	BUY	$43.36 - $53.53 $357,936 - $441,890	8,255 Added 45.92%	26,231 $1.2 Million
Q2 2020 Aug 12, 2020	BUY	$46.37 - $57.58 $148,894 - $184,889	3,211 Added 21.75%	17,976 $904,000
Q1 2020 May 13, 2020	SELL	$40.22 - $62.0 $1.35 Million - $2.08 Million	-33,605 Reduced 69.47%	14,765 $759,000
Q4 2019 Feb 10, 2020	BUY	$57.95 - $66.61 $702,064 - $806,980	12,115 Added 33.42%	48,370 $2.99 Million
Q3 2019 Nov 14, 2019	SELL	$60.08 - $88.17 $23,130 - $33,945	-385 Reduced 1.05%	36,255 $2.18 Million
Q2 2019 Aug 14, 2019	SELL	$81.3 - $97.35 $1.59 Million - $1.91 Million	-19,584 Reduced 34.83%	36,640 $3.09 Million
Q1 2019 May 15, 2019	BUY	$69.08 - $105.66 $3.11 Million - $4.75 Million	44,990 Added 400.48%	56,224 $5.37 Million
Q4 2018 Feb 14, 2019	SELL	$65.41 - $84.65 $1.13 Million - $1.46 Million	-17,299 Reduced 60.63%	11,234 $795,000
Q3 2018 Nov 14, 2018	BUY	$85.46 - $126.37 $1.97 Million - $2.92 Million	23,078 Added 423.06%	28,533 $2.44 Million
Q2 2018 Aug 14, 2018	SELL	$81.85 - $120.51 $216,247 - $318,387	-2,642 Reduced 32.63%	5,455 $632,000
Q1 2018 May 15, 2018	SELL	$57.91 - $92.15 $1.09 Million - $1.74 Million	-18,863 Reduced 69.97%	8,097 $654,000
Q4 2017 Feb 14, 2018	BUY	$45.65 - $59.37 $14,836 - $19,295	325 Added 1.22%	26,960 $1.58 Million
Q3 2017 Nov 14, 2017	BUY	$37.91 - $46.8 $1.01 Million - $1.25 Million	26,635	26,635 $1.25 Million

Others Institutions Holding ENTA

# of Institutions

108

Shares Held

19.7M

Call Options Held

9.7K

Put Options Held

12.4K

View Full List

About ENANTA PHARMACEUTICALS INC

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $140M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

More about ENTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account